Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 14 09 2020
revised: 06 11 2020
accepted: 17 11 2020
pubmed: 7 12 2020
medline: 29 1 2021
entrez: 6 12 2020
Statut: ppublish

Résumé

Early diagnosis of coronavirus disease 2019 (COVID-19) is of the utmost importance but remains challenging. The objective of the current study was to characterize exhaled breath from mechanically ventilated adults with COVID-19. In this prospective observational study, we used real-time, online, proton transfer reaction time-of-flight mass spectrometry to perform a metabolomic analysis of expired air from adults undergoing invasive mechanical ventilation in the intensive care unit due to severe COVID-19 or non-COVID-19 acute respiratory distress syndrome (ARDS). Between March 25 The real-time, non-invasive detection of methylpent-2-enal, 2,4-octadiene 1-chloroheptane, and nonanal in exhaled breath may identify ARDS patients with COVID-19. The study was funded by Agence Nationale de la Recherche (SoftwAiR, ANR-18-CE45-0017 and RHU4 RECORDS, Programme d'Investissements d'Avenir, ANR-18-RHUS-0004), Région Île de France (SESAME 2016), and Fondation Foch.

Sections du résumé

BACKGROUND BACKGROUND
Early diagnosis of coronavirus disease 2019 (COVID-19) is of the utmost importance but remains challenging. The objective of the current study was to characterize exhaled breath from mechanically ventilated adults with COVID-19.
METHODS METHODS
In this prospective observational study, we used real-time, online, proton transfer reaction time-of-flight mass spectrometry to perform a metabolomic analysis of expired air from adults undergoing invasive mechanical ventilation in the intensive care unit due to severe COVID-19 or non-COVID-19 acute respiratory distress syndrome (ARDS).
FINDINGS RESULTS
Between March 25
INTERPRETATION CONCLUSIONS
The real-time, non-invasive detection of methylpent-2-enal, 2,4-octadiene 1-chloroheptane, and nonanal in exhaled breath may identify ARDS patients with COVID-19.
FUNDING BACKGROUND
The study was funded by Agence Nationale de la Recherche (SoftwAiR, ANR-18-CE45-0017 and RHU4 RECORDS, Programme d'Investissements d'Avenir, ANR-18-RHUS-0004), Région Île de France (SESAME 2016), and Fondation Foch.

Identifiants

pubmed: 33279860
pii: S2352-3964(20)30530-2
doi: 10.1016/j.ebiom.2020.103154
pmc: PMC7714658
pii:
doi:

Substances chimiques

Volatile Organic Compounds 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103154

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Références

J Breath Res. 2014 Mar;8(1):014001
pubmed: 24421258
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Sci Rep. 2015 Nov 26;5:17179
pubmed: 26608483
Eur Respir J. 2014 May;43(5):1522-5
pubmed: 24789953
J Proteome Res. 2015 Aug 7;14(8):3322-35
pubmed: 26088811
Respir Med. 2018 Mar;136:111-117
pubmed: 29501241
J Breath Res. 2017 Jan 09;11(1):016005
pubmed: 28068288
Eur Respir J. 2014 Jul;44(1):188-97
pubmed: 24743964
J Breath Res. 2016 Jun 16;10(3):036001
pubmed: 27310311
Bioanalysis. 2013 Jun;5(11):1443-59
pubmed: 23742311
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Eur Respir J. 2013 Jan;41(1):183-8
pubmed: 23277518
Intensive Care Med. 1998 May;24(5):415-21
pubmed: 9660254
Eur Respir J. 2004 Dec;24(6):1011-7
pubmed: 15572547
J Infect. 2017 Nov;75(5):441-447
pubmed: 28804027
Respir Med. 2015 Nov;109(11):1454-9
pubmed: 26440675
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
BMC Bioinformatics. 2009 Feb 19;10:62
pubmed: 19228411
J Breath Res. 2019 Jul 09;13(4):046004
pubmed: 31185457
Trends Biotechnol. 2014 Oct;32(10):538-48
pubmed: 25179940
J Biochem Mol Biol. 2003 Jan 31;36(1):95-109
pubmed: 12542980
Anal Chem. 2013 Nov 5;85(21):10321-9
pubmed: 24044609
J Breath Res. 2014 Sep;8(3):034001
pubmed: 24946087
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Sci Rep. 2018 Oct 5;8(1):14857
pubmed: 30291257
Clin Infect Dis. 2014 Dec 15;59(12):1733-40
pubmed: 25342502
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
BMC Pulm Med. 2014 Apr 26;14:72
pubmed: 24767549
J Breath Res. 2015 Jan 05;9(1):016004
pubmed: 25557917

Auteurs

Stanislas Grassin-Delyle (S)

Hôpital Foch, Exhalomics®, Département des maladies des voies respiratoires, Suresnes, France (S.G.D., H.S., E.N., L-J.C., P.D.); Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation, Montigny le Bretonneux, France (S.G.D., P.M., N.H., D.A.); FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) (S.G.D., H.S., E.N., L-J.C., P.D., E.T., D.A.).. Electronic address: stanislas.grassin-delyle@uvsq.fr.

Camille Roquencourt (C)

CEA, LIST, Laboratoire Sciences des Données et de la Décision, Gif-sur-Yvette, France (C.R.).

Pierre Moine (P)

Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation, Montigny le Bretonneux, France (S.G.D., P.M., N.H., D.A.); Intensive Care Unit, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Garches, France (P.M., G.S., S.C., N.H., J.F., D.A.).

Gabriel Saffroy (G)

Intensive Care Unit, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Garches, France (P.M., G.S., S.C., N.H., J.F., D.A.).

Stanislas Carn (S)

Intensive Care Unit, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Garches, France (P.M., G.S., S.C., N.H., J.F., D.A.).

Nicholas Heming (N)

Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation, Montigny le Bretonneux, France (S.G.D., P.M., N.H., D.A.); Intensive Care Unit, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Garches, France (P.M., G.S., S.C., N.H., J.F., D.A.).

Jérôme Fleuriet (J)

Intensive Care Unit, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Garches, France (P.M., G.S., S.C., N.H., J.F., D.A.).

Hélène Salvator (H)

Hôpital Foch, Exhalomics®, Département des maladies des voies respiratoires, Suresnes, France (S.G.D., H.S., E.N., L-J.C., P.D.); FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) (S.G.D., H.S., E.N., L-J.C., P.D., E.T., D.A.).

Emmanuel Naline (E)

Hôpital Foch, Exhalomics®, Département des maladies des voies respiratoires, Suresnes, France (S.G.D., H.S., E.N., L-J.C., P.D.); FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) (S.G.D., H.S., E.N., L-J.C., P.D., E.T., D.A.).

Louis-Jean Couderc (LJ)

Hôpital Foch, Exhalomics®, Département des maladies des voies respiratoires, Suresnes, France (S.G.D., H.S., E.N., L-J.C., P.D.); FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) (S.G.D., H.S., E.N., L-J.C., P.D., E.T., D.A.).

Philippe Devillier (P)

Hôpital Foch, Exhalomics®, Département des maladies des voies respiratoires, Suresnes, France (S.G.D., H.S., E.N., L-J.C., P.D.); FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) (S.G.D., H.S., E.N., L-J.C., P.D., E.T., D.A.).

Etienne A Thévenot (EA)

Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, MetaboHUB, Gif-sur-Yvette, France (E.T.); FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) (S.G.D., H.S., E.N., L-J.C., P.D., E.T., D.A.).

Djillali Annane (D)

Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation, Montigny le Bretonneux, France (S.G.D., P.M., N.H., D.A.); Intensive Care Unit, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Garches, France (P.M., G.S., S.C., N.H., J.F., D.A.); FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) (S.G.D., H.S., E.N., L-J.C., P.D., E.T., D.A.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH